Follow

Submissions from 2021

Link

Cytokine-induced liver injury in coronavirus disease-2019 (COVID-19): untangling the knots., P. Anirvan, S. Narain, N. Hajizadeh, F. Z. Aloor, S. P. Singh, and S. K. Satapathy

Link

Cytokine-induced liver injury in coronavirus disease-2019 (COVID-19): untangling the knots., P. Anirvan, S. Narain, N. Hajizadeh, F. Z. Aloor, S. P. Singh, and S. K. Satapathy

Link

Post-COVID-19 Cholangiopathy: A Novel Entity., N. C. Roth, A. Kim, T. Vitkovski, J. Xia, G. Ramirez, D. Bernstein, and J. M. Crawford

Link

Severity of liver test abnormalities in coronavirus disease 2019 depends on comorbidities and predicts early in-hospital mortality., S. K. Satapathy, C. Kuntzen, H. Qiu, Y. Jiang, H. C. Bodenheimer, N. C. Roth, J. S. Hirsch, A. J. Trindade, D. E. Bernstein, and Northwell Health COVID-19 Research Consortium

Submissions from 2020

PDF

PRO: Portal Vein Thrombosis Impacts Liver Transplantation Outcomes, U. Agbim and S. K. Satapathy

PDF

Outcomes of Liver Transplant Recipients with Acute-on-Chronic Liver Failure Based on EASL-CLIF Consortium Definition: A Single-center Study, U. Agbim, A. Sharma, B. Maliakkal, S. Karri, M. Yazawa, W. Goldkamp, P. S. Podila, J. M. Vanatta, H. Gonzalez, S. K. Satapathy, and +3 additional authors

Link

Effect of opioid treatment on clinical outcomes among cirrhotic patients in the United States, B. Ali, Y. Jiang, U. Agbim, S. K. Kedia, S. K. Satapathy, M. Barnes, B. Maliakkal, S. P. Nair, J. D. Eason, and H. C. Gonzalez

PDF

Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome — what we know so far, P. Anirvan, P. Bharali, M. Gogoi, P. J. Thuluvath, S. P. Singh, and S. K. Satapathy

Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States, D. T. Dieterich, D. Bernstein, S. Flamm, P. J. Pockros, and N. Reau

PDF

Nafld epidemiology, emerging pharmacotherapy, liver transplantation implications and the trends in the United States, C. Gadiparthi, M. Spatz, S. Greenberg, U. Iqbal, S. Kanna, S. K. Satapathy, A. Broder, and A. Ahmed

Link

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension, G. Garcia-Tsao, J. Bosch, Z. Kayali, S. A. Harrison, M. F. Abdelmalek, E. Lawitz, S. K. Satapathy, M. Ghabril, S. Satapathy, B. Muellhaupt, and +63 additional authors

PDF

Acute Liver Failure in a COVID-19 Patient Without any Preexisting Liver Disease., D. Gurala, H. Al Moussawi, J. Philipose, and J. R. Abergel

Link

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis, S. A. Harrison, Z. Goodman, A. Jabbar, R. Vemulapalli, Z. H. Younes, B. Freilich, M. Y. Sheikh, J. M. Schattenberg, S. K. Satapathy, A. J. Sanyal, and +10 additional authors

PDF

Elevated Liver Biochemistries in Hospitalized Chinese Patients with Severe COVID-19: Systematic Review and Meta-analysis., A. J. Kovalic, G. Huang, P. J. Thuluvath, and S. K. Satapathy

Link

Reply to Letter to the Editor: Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-Analysis., A. J. Kovalic, G. Huang, P. J. Thuluvath, and S. K. Satapathy

Link

Thromboelastography versus standard coagulation testing in the assessment and reversal of coagulopathy among cirrhotics: a systematic review and meta-analysis, A. J. Kovalic, M. A. Khan, D. Malaver, M. J. Whitson, L. W. Teperman, D. E. Bernstein, A. Singal, and S. K. Satapathy

Systematic review with meta-analysis: abnormalities in the International Normalised Ratio (INR) do not correlate with periprocedural bleeding events among patients with cirrhosis, A. J. Kovalic, C. N. Majeed, N. S. Samji, P. J. Thuluvath, and S. K. Satapathy

PDF

Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis, A. J. Kovalic, S. K. Satapathy, and P. J. Thuluvath

PDF

Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease, H. K. Marella, Y. K. Reddy, Y. Jiang, S. Ganguli, P. S. Podila, P. D. Snell, A. J. Kovalic, G. Cholankeril, A. K. Singal, S. K. Satapathy, and +2 additional authors

Link

Acute on chronic liver failure from novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), H. Qiu, P. Wander, D. Bernstein, and S. K. Satapathy

Link

Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies, Y. K. Reddy, H. K. Marella, Y. Jiang, S. Ganguli, P. Snell, P. S. Podila, B. Maliakkal, and S. K. Satapathy

Link

Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma, N. E. Rich, J. D. Yang, P. V. Perumalswami, N. Alkhouri, W. Jackson, N. D. Parikh, N. Mehta, R. Salgia, S. K. Satapathy, A. G. Singal, and +37 additional authors

Link

Treatment Options for Thrombocytopenia in Patients with Chronic Liver Disease Undergoing a Scheduled Procedure, S. Saab, D. Bernstein, T. Hassanein, M. Kugelmas, and P. Kwo

Link

Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis, N. S. Samji, R. Heda, A. J. Kovalic, and S. K. Satapathy

PDF

Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates, N. S. Samji, R. Heda, and S. K. Satapathy

PDF

Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease, N. S. Samji, P. D. Snell, A. K. Singal, and S. K. Satapathy

Link

Treating Portopulmonary Hypertension with Macitentan: Smoking Gun or Magic bullet?, S. K. Satapathy and B. L. Da

PDF

A pilot study of ex-vivo MRI-PDFF of donor livers for assessment of steatosis and predicting early graft dysfunction, S. K. Satapathy, H. C. Gonzalez, J. Vanatta, A. Dyer, W. Angel, S. S. Nouer, M. Kocak, S. K. Kedia, Y. Jiang, J. D. Eason, and +11 additional authors

Link

Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox, S. K. Satapathy, Y. Jiang, U. Agbim, C. Wu, D. E. Bernstein, L. W. Teperman, S. K. Kedia, G. P. Aithal, K. R. Bhamidimarri, A. K. Singal, and +11 additional authors

Link

African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians., S. K. Satapathy, H. K. Marella, R. P. Heda, S. Ganguli, Y. Kirthi Reddy, P. S. B. Podila, I. Clark, and B. Maliakkal

Link

Predicting Harmful Alcohol Relapse after Liver Transplant: The HALT Score., S. K. Satapathy, C. Thornburgh, R. Heda, Y. Jiang, S. K. Kedia, S. P. Nair, J. D. Eason, and D. Maluf

PDF

Role of Nutraceuticals in COVID-19 Mediated Liver Dysfunction., M. Sikander, S. Malik, A. Rodriguez, M. M. Yallapu, A. S. Narula, S. K. Satapathy, V. Dhevan, S. C. Chauhan, and M. Jaggi

Link

Increasing Burden of Acute-On-Chronic Liver Failure among Alcohol-Associated Liver Disease in the Young Population in the United States, A. K. Singal, S. Arora, R. J. Wong, S. K. Satapathy, V. H. Shah, Y. F. Kuo, and P. S. Kamath

Link

Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma, A. K. Singal, S. K. Satapathy, N. Reau, R. Wong, and Y. F. Kuo

PDF

What GI Physicians Need to Know During COVID-19 Pandemic, P. J. Thuluvath, J. J. Alukal, N. Ravindran, and S. K. Satapathy

Link

Use of HCV-Positive Livers in HCV-Negative Recipients., P. J. Thuluvath, D. A. Bruno, J. Alukal, S. K. Satapathy, A. J. Thuluvath, and T. Zhang

Link

Use of HCV-Positive Livers in HCV-Negative Recipients., P. J. Thuluvath, D. A. Bruno, J. Alukal, S. K. Satapathy, A. J. Thuluvath, and T. Zhang

PDF

COVID-19 Presenting as Acute Hepatitis, P. Wander, M. Epstein, and D. Bernstein

Link

Association between post-transplant donor-specific antibodies and recipient outcomes in simultaneous liver–kidney transplant recipients: single-center, cohort study, M. Yazawa, O. Cseprekal, R. A. Helmick, M. Talwar, V. Balaraman, P. S. Podila, U. A. Agbim, B. Maliakkal, S. K. Satapathy, M. Z. Molnar, and +5 additional authors

Lack of Association between Pretransplant Donor-Specific Antibodies and Posttransplant Kidney Outcomes in Simultaneous Liver-Kidney Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Steroid-Free Protocol, M. Yazawa, O. Cseprekal, R. A. Helmick, M. Talwar, V. Balaraman, P. S. Podila, U. A. Agbim, B. Maliakkal, S. K. Satapathy, M. Z. Molnar, and +5 additional authors

PDF

Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver–kidney transplant recipients, M. Yazawa, O. Cseprekal, R. A. Helmick, M. Talwar, V. Balaraman, P. S. Podila, S. Fossey, S. K. Satapathy, J. D. Eason, and M. Z. Molnar

PDF

Longitudinal Renal Function in Liver Transplant Recipients With Acute-on-Chronic Liver Failure, M. Yazawa, B. Maliakkal, S. Nair, P. S. Podila, U. A. Agbim, S. Karri, S. D. Khan, D. Maluf, J. D. Eason, S. K. Satapathy, and +1 additional author

Link

Kidney Graft Outcomes in High Immunological Risk Simultaneous Liver-Kidney Transplants, M. Yazawa, S. K. Satapathy, and M. Z. Molnar

PDF

Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis., S. Young, R. Tariq, J. Provenza, S. K. Satapathy, K. Faisal, A. Choudhry, S. L. Friedman, and A. K. Singal

Submissions from 2019

Link

Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C., C. Q. Pan, B. C. Tiongson, K.Q. Hu, S-H. B. Han, M. Tong, D. Chu, J. Park, T. P. Lee, K. R. Bhamidimarri, D. Wang, and +3 additional authors

Link

Drug-Induced Liver Injury Due to Dulaglutide Use, A. V. Patel, P. M. Jotwani, and T. P. Lee

Link

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis, F. Poordad, S. Sedghi, P. J. Pockros, N. Ravendhran, R. Reindollar, M. R. Lucey, M. Epstein, L. Bank, D. Bernstein, D. R. Nelson, and +5 additional authors

Link

Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges, N. S. Samji, R. Verma, K. C. Keri, A. K. Singal, A. Ahmed, M. Rinella, D. Bernstein, M. F. Abdelmalek, and S. K. Satapathy

Submissions from 2018

Link

Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic Preface, D. E. Bernstein

PDF

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin, J. J. Feld, D. E. Bernstein, Z. Younes, H. Van Vlierberghe, L. Larsen, F. Tatsch, and P. Ferenci

Link

Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, C. K. Hung and H. C. Bodenheimer

Link

Response to Perrella et al, P. Y. Kwo, M. L. Shiffman, and D. E. Bernstein

Link

The cochrane review conclusion for Hepatitis C DAA therapies is wrong, P. Y. Kwo, M. L. Shiff, and D. E. Bernstein

Link

Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics, H. W. Lim and D. E. Bernstein

PDF

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure, F. Poordad, S. Pol, A. Asatryan, M. Buti, D. Shaw, C. Hezode, F. Felizarta, R. W. Reindollar, D. E. Bernstein, F. J. Mensa, and +10 additional authors

Link

A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy., D. K. Rex, R. Bhandari, T. Desta, M. P. DeMicco, C. Schaeffer, K. Etzkorn, C. F. Barish, R. Pruitt, B. D. Cash, D. Bernstein, and +3 additional authors

PDF

Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial, J. Thompson, N. Jones, A. Al-Khafaji, S. Malik, D. Reich, S. Munoz, R. MacNicholas, T. Hassanein, A. Duddempudi, R. Subramanian, and +33 additional authors

Link

Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography, E. Tsai and T. P. Lee

Submissions from 2017

Link

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study., D. Jones, P. F. Boudes, M. G. Swain, C. L. Bowlus, M. R. Galambos, B. R. Bacon, Y. Doerffel, N. Gitlin, D. E. Bernstein, G. M. Hirschfield, and +26 additional authors

PDF

Glecaprevir and Pibrentasvir for 12 Weeks for Hepatitis C Virus Genotype 1 Infection and Prior Direct-Acting Antiviral Treatment, F. Poordad, F. Felizarta, A. Asatryan, M. S. Sulkowski, R. W. Reindollar, C. S. Landis, S. C. Gordon, S. L. Flamm, D. E. Bernstein, F. J. Mensa, and +6 additional authors

Link

Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update, G. Shiha, A. Ibrahim, A. Helmy, S. K. Sarin, M. Omata, A. Kumar, D. Bernstien, H. Maruyama, V. Saraswat, Y. Chawla, S. Hamid, Z. Abbas, P. Bedossa, P. Sakhuja, M. Elmahatab, S. G. Lim, L. Lesmana, J. Sollano, J.D. Jia, and M. Kumar

Submissions from 2016

Link

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks, J. J. Feld, C. Moreno, R. Trinh, E. Tam, S. Bourgeois, Y. Horsmans, M. Elkhashab, D. E. Bernstein, N. S. Shulman, F. Poordad, and +7 additional authors

PDF

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial, E. J. Gane, K. V. Kowdley, D. Pound, C. A.M. Stedman, M. Davis, K. Etzkorn, S. C. Gordon, D. Bernstein, P. Y. Kwo, M. H. Nguyen, and +14 additional authors

PDF

Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study, P. Kwo, N. Gitlin, R. Nahass, D. Bernstein, K. Etzkorn, S. Rojter, E. Schiff, M. Davis, P. Ruane, J. Witek, and +8 additional authors

PDF

Efficacy of Direct-Acting Antiviral Combination for Patients with Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease, P. J. Pockros, K. R. Reddy, P. S. Mantry, E. Cohen, M. Bennett, M. S. Sulkowski, D. E. Bernstein, D. E. Cohen, N. S. Shulman, E. Lawitz, and +4 additional authors

Submissions from 2015

Link

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid, G. M. Hirschfield, A. Mason, V. Luketic, K. Lindor, S. C. Gordon, M. Mayo, K. V. Kowdley, C. Vincent, H. C. Bodhenheimer Jr., D. Shapiro, and +8 additional authors

PDF

Hepatic manifestations of non-steroidal inflammatory bowel disease therapy, R. Hirten, K. Sultan, A. Thomas, and D. E. Bernstein

Link

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders, D. Jensen, K. E. Sherman, C. Hezode, S. Pol, S. Zeuzem, V. de Ledinghen, A. Tran, M. Elkhashab, D. Bernstein, S. Noviello, and +13 additional authors

PDF

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study, D. R. Nelson, J. N. Cooper, J. P. Lalezari, E. Lawitz, P. J. Pockros, N. Gitlin, B. F. Freilich, Z. H. Younes, D. Berastein, E. A. Hughes, and +15 additional authors

Submissions from 2014

Link

Hepatitis B and C, A. T. Duddempudi and D. E. Bernstein

Link

ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV, P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, C. Cooper, E. Tam, R. T. Marinho, N. Tsai, K. R. Reddy, and +19 additional authors

Link

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis, K. V. Kowdley, S. C. Gordon, K. R. Reddy, L. Rossaro, D. E. Bernstein, E. Lawitz, M. L. Shiffman, E. Schiff, R. Ghalib, M. W. Fried, and +15 additional authors